Dendrite Announces Innovative Solution to Make Life Science Sales Force Technology More Affordable, Portable and Scalable

  
    
  
  
    
      Dendrite International, Inc. (NASDAQ: DRTE), a leading provider of 
      pharmaceutical industry solutions, today announced the launch of 
      Dendrite MICRO™, a mobile phone enabled sales 
      force effectiveness (SFE) solution designed specifically for life 
      science companies with smaller sales forces. Dendrite MICRO is the first 
      application to be developed on the Company’s 
      recently announced mobile development environment, and provides a 
      convenient, portable and affordable way for emerging life science 
      companies to increase sales force productivity.
    
    
      Dendrite MICRO was specifically designed for life science companies with 
      smaller sales forces, such as medical device companies, and emerging or 
      specialty pharmaceutical companies that require sales force automation 
      technology without the investment of an enterprise solution. The latest 
      offering capitalizes on the robust architecture of Dendrite’s 
      highly scalable flagship SFE platform. Accordingly, companies that begin 
      using Dendrite MICRO as an entry level product have the flexibility to 
      scale the solution to meet changing needs as their sales forces grow.
    
    
      Dendrite MICRO is a mobile phone-based solution that features low 
      up-front investment costs, an easy monthly subscription fee and a 
      preconfigured design for quick deployment without the necessity of 
      complex implementation and training. The solution makes full use of 
      mobile technology with functions like “Near Me,” 
      especially useful for pharmaceutical companies to identify targeted 
      doctors that are closest to the sales representatives, so they can 
      easily fill suddenly cancelled appointments. Dendrite MICRO features the 
      functionality necessary to enable the company to effectively target the 
      right doctor at the right time and with the right message for maximum 
      effectiveness.
    
    
      “Dendrite MICRO is the first of what will be 
      many innovative solutions to be developed on our new mobile development 
      environment announced in August,” said John 
      Bailye, Dendrite’s chairman and chief 
      executive officer. “We are excited about 
      driving mobile innovation into the pharmaceutical and life science 
      market by introducing solutions that will enable both large global 
      enterprises as well as emerging companies tap into the convenience and 
      power of mobile technology.”
    
    
      To learn more about Dendrite MICRO, visit www.dendrite.com/micro.
    
    
      About Dendrite
    
    
      Founded in 1986, Dendrite International (NASDAQ: DRTE) enables sales, 
      marketing, clinical and compliance solutions for the global 
      pharmaceutical industry. The Company’s 
      clients are located in more than 50 countries and include the world's 
      top 20 pharmaceutical companies.
    
    
      Note: Dendrite is a registered trademark of Dendrite International, Inc.
    
    
      This document may contain forward-looking statements that may be 
      identified by such forward-looking terminology as "expect," "believe," 
      "anticipate," "will," "intend," "plan," "target," "outlook," "guidance," 
      and similar statements or variations. Such forward-looking statements 
      are based on our current expectations, estimates, assumptions and 
      projections and involve significant risks and uncertainties, including 
      risks which may result from our dependence on the pharmaceutical 
      industry; fluctuations in quarterly revenues due to lengthy sales and 
      implementation cycles for certain of our solutions; our fixed expenses 
      in relation to fluctuating revenues and variations in customers' budget 
      cycles; dependence on certain major customers; changes in demand for our 
      products and services attributable to any weakness experienced in the 
      economy or mergers, acquisitions and consolidations in the 
      pharmaceutical industry; successful and timely development and 
      introduction of new products and versions; rapid technological changes; 
      increased competition; international operations; integrating the 
      entities we acquire; our ability to effectively manage our growth; the 
      protection of our proprietary technology; our ability to compete in the 
      Internet-related products and services market; the continued demand for 
      Internet-related products and services; the ability of our third party 
      vendors to respond to technological change; our ability to maintain our 
      relationships with third-party vendors; less favorable than anticipated 
      results from strategic relationships; dependence of data solutions on 
      strategic relationships; events which may affect the U.S. and world 
      economies; and catastrophic events which could negatively affect our 
      information technology infrastructure. Other important factors that 
      should be reviewed and carefully considered are included in the 
      company's 10-K, 10-Qs, and other reports filed with the SEC. Actual 
      results may differ materially. The company assumes no obligation for 
      updating any such forward-looking statements to reflect actual results, 
      changes in assumptions or other changes affecting such forward-looking 
      statements.
    
  
Dendrite International, Inc. (NASDAQ: DRTE), a leading provider of
pharmaceutical industry solutions, today announced the launch of
Dendrite MICRO(TM), a mobile phone enabled sales force effectiveness
(SFE) solution designed specifically for life science companies with
smaller sales forces. Dendrite MICRO is the first application to be
developed on the Company's recently announced mobile development
environment, and provides a convenient, portable and affordable way
for emerging life science companies to increase sales force
productivity.

   Dendrite MICRO was specifically designed for life science
companies with smaller sales forces, such as medical device companies,
and emerging or specialty pharmaceutical companies that require sales
force automation technology without the investment of an enterprise
solution. The latest offering capitalizes on the robust architecture
of Dendrite's highly scalable flagship SFE platform. Accordingly,
companies that begin using Dendrite MICRO as an entry level product
have the flexibility to scale the solution to meet changing needs as
their sales forces grow.

   Dendrite MICRO is a mobile phone-based solution that features low
up-front investment costs, an easy monthly subscription fee and a
preconfigured design for quick deployment without the necessity of
complex implementation and training. The solution makes full use of
mobile technology with functions like "Near Me," especially useful for
pharmaceutical companies to identify targeted doctors that are closest
to the sales representatives, so they can easily fill suddenly
cancelled appointments. Dendrite MICRO features the functionality
necessary to enable the company to effectively target the right doctor
at the right time and with the right message for maximum
effectiveness.

   "Dendrite MICRO is the first of what will be many innovative
solutions to be developed on our new mobile development environment
announced in August," said John Bailye, Dendrite's chairman and chief
executive officer. "We are excited about driving mobile innovation
into the pharmaceutical and life science market by introducing
solutions that will enable both large global enterprises as well as
emerging companies tap into the convenience and power of mobile
technology."

   To learn more about Dendrite MICRO, visit www.dendrite.com/micro.

   About Dendrite

   Founded in 1986, Dendrite International (NASDAQ: DRTE) enables
sales, marketing, clinical and compliance solutions for the global
pharmaceutical industry. The Company's clients are located in more
than 50 countries and include the world's top 20 pharmaceutical
companies.

   Note: Dendrite is a registered trademark of Dendrite
International, Inc.

   This document may contain forward-looking statements that may be
identified by such forward-looking terminology as "expect," "believe,"
"anticipate," "will," "intend," "plan," "target," "outlook,"
"guidance," and similar statements or variations. Such forward-looking
statements are based on our current expectations, estimates,
assumptions and projections and involve significant risks and
uncertainties, including risks which may result from our dependence on
the pharmaceutical industry; fluctuations in quarterly revenues due to
lengthy sales and implementation cycles for certain of our solutions;
our fixed expenses in relation to fluctuating revenues and variations
in customers' budget cycles; dependence on certain major customers;
changes in demand for our products and services attributable to any
weakness experienced in the economy or mergers, acquisitions and
consolidations in the pharmaceutical industry; successful and timely
development and introduction of new products and versions; rapid
technological changes; increased competition; international
operations; integrating the entities we acquire; our ability to
effectively manage our growth; the protection of our proprietary
technology; our ability to compete in the Internet-related products
and services market; the continued demand for Internet-related
products and services; the ability of our third party vendors to
respond to technological change; our ability to maintain our
relationships with third-party vendors; less favorable than
anticipated results from strategic relationships; dependence of data
solutions on strategic relationships; events which may affect the U.S.
and world economies; and catastrophic events which could negatively
affect our information technology infrastructure. Other important
factors that should be reviewed and carefully considered are included
in the company's 10-K, 10-Qs, and other reports filed with the SEC.
Actual results may differ materially. The company assumes no
obligation for updating any such forward-looking statements to reflect
actual results, changes in assumptions or other changes affecting such
forward-looking statements.